IKT
NASDAQ · Biotechnology
Inhibikase Therapeutics Inc
$1.52
-0.01 (-0.65%)
Open$1.56
Previous Close$1.53
Day High$1.58
Day Low$1.49
52W High$2.61
52W Low$1.40
Volume—
Avg Volume557.3K
Market Cap213.21M
P/E Ratio—
EPS$-0.50
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+1,742.8% upside
Current
$1.52
$1.52
Target
$28.01
$28.01
$19.41
$28.01 avg
$39.32
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 78.22M | 74.95M | 61.90M |
| Net Income | 4.38M | 5.16M | 3.75M |
| Profit Margin | 5.6% | 6.9% | 6.1% |
| EBITDA | 7.32M | 7.08M | 6.90M |
| Free Cash Flow | 4.21M | 5.04M | 4.89M |
| Rev Growth | +8.7% | +15.3% | -5.1% |
| Debt/Equity | 0.35 | 0.45 | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $469.15 | +0.75% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $542.98 | +0.81% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $959.96 | +0.47% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $161.38 | -2.22% | 7.7 | 20.98B |